Literature DB >> 15291374

How important is optimal blood pressure control?

Gordon T McInnes1.   

Abstract

BACKGROUND: Evidence for the cardiovascular benefits of antihypertensive treatment is among the strongest in medicine. Randomized, prospective, unconfounded studies in thousands of people have shown that even small reductions in blood pressure for short periods substantially improve cardiovascular outcomes. Recent evidence has emphasized the importance of optimal blood pressure control, particularly in patients with high cardiovascular risk, such as those with type 2 diabetes mellitus.
OBJECTIVE: This article discusses optimal target blood pressure goals, reviews the effects of antihypertensive treatment in high-risk patients, presents current guidelines for blood pressure control, discusses the failure worldwide to achieve such control, and suggests approaches to improved treatment.
CONCLUSIONS: In high-risk patients, small improvements in blood pressure control are associated with large reductions in cardiovascular risk. National and international guidelines for the management of hypertension therefore now recommend rigorous blood pressure targets. Despite extensive clinical evidence, the delivery of care for hypertension remains unsatisfactory. Hypertension is underdiagnosed and undertreated, and recommended target blood pressures are rarely achieved. Physicians appear reluctant to make changes to treatment, which would lead to more effective use of antihypertensive drugs. Overwhelming evidence supports the benefit of optimal blood pressure control in patients with hypertension. Several studies have shown that such control can be achieved, but most likely requires combination treatment. Combination treatment is likely to be successful only if drugs are well tolerated and patients are compliant. The angiotensin II receptor antagonists (sartans) have the therapeutic advantage of efficacy, excellent tolerability, and a good record of compliance. Blood pressure control can be more easily accomplished by using sartans early in treatment and by recognizing the benefits of even small reductions in blood pressure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15291374     DOI: 10.1016/s0149-2918(04)90140-3

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  8 in total

Review 1.  Can we justify goal blood pressure of <140/90 mm Hg in most hypertensives?

Authors:  Raymond R Townsend
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

2.  Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension.

Authors:  S G Chrysant; J Lee; M Melino; S Karki; R Heyrman
Journal:  J Hum Hypertens       Date:  2010-02-18       Impact factor: 3.012

3.  Quinapril for treatment of hypertension in Turkey: dose titration and diuretic combination treatment strategies.

Authors:  Gul Yener; Sinan Aran; Mithat Bahceci; Kurtulus Ozdemir; Fusun Gultekin; Wing Lowe
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

4.  Factors affecting adherence to antihypertensive medication in Greece: results from a qualitative study.

Authors:  Vassiliki Tsiantou; Polina Pantzou; Elpida Pavi; George Koulierakis; John Kyriopoulos
Journal:  Patient Prefer Adherence       Date:  2010-09-07       Impact factor: 2.711

5.  Effect of an emergency department education and empowerment intervention on uncontrolled hypertension in a predominately minority population: The AHEAD2 randomized clinical pilot trial.

Authors:  Heather Prendergast; Marina Del Rios; Ramon Durazo-Arvizu; Sandra Escobar-Schulz; Sara Heinert; Maya Jackson; Renee Petzel Gimbar; Martha Daviglus; Brenda Lara; Shaveta Khosla
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-03-02

Review 6.  Blood pressure control in patients with comorbidities.

Authors:  Roland E Schmieder; Luis M Ruilope
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-08       Impact factor: 3.738

Review 7.  Compliance and fixed-dose combination therapy.

Authors:  Sripal Bangalore; Anupama Shahane; Sanobar Parkar; Franz H Messerli
Journal:  Curr Hypertens Rep       Date:  2007-06       Impact factor: 4.592

Review 8.  Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk.

Authors:  H Haller
Journal:  Int J Clin Pract       Date:  2008-03-17       Impact factor: 2.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.